Overview
Dr. Lee completed his undergraduate degree at Duke University (Durham, NC), and then moved to the University of Pennsylvania (Philadelphia, PA) to complete both his MD and his MBA. He then moved to New York and began working at Weill Cornell Medical College/New York-Presbyterian Hospital, specifically within the Department of Urology, while completing both his residency rotation and a fellowship.
Dr. Lee was appointed to a full-time faculty position within the Department of Urology in July 2011 after completing his fellowship. He currently practices within the Iris Cantor Men's Health Center, which is located at 425 E 61st St, 12th floor.
While completing his residency at Weill Cornell Medical College, Dr. Lee was awarded the Society for Male Reproduction and Urology (SMRU) Traveling Scholar Award (2006), the Society for the Study of Male Reproduction (SSMR) Men’s Health Traveling Fellowship (2007), the Empire Clinical Research Investigator Program Grant (2007), the New York Weill Cornell Medical Center Alumni Council Distinguished Housestaff Award (2008), and the Doctors of the World Health and Human Rights Leadership Award (2008).
Dr. Lee is an active participant in translational research and is currently involved in several protocols as either primary or co-investigator that includes NIH, non-profit foundation, and industry support. He takes part in the peer review process of other’s research as a journal reviewer for European Urology, Journal of Urology, British Journal of Urology International, and Advances in Urology.
His current research interests include BPH, male and female pelvic health, female urology, incontinence, pelvic organ prolapse, health outcomes, cost effectiveness analysis, pelvic reconstruction, bioengineering, and nanoparticle therapy.
Dr. Lee's office is located within the Iris Cantor Men's Health Center at 425 E. 61st Street. You may contact the office with questions or to make an appointment at 646-962-4811.
Highlights
- 1The Lancet. Global health · 2022
- 2PloS one · 2020
- 3Advances in experimental medicine and biology · 2021
Publications
Funding
Active
4 grants- MPIINV-003436A Training Infrastructure to Support Voluntary Male Circumcision in sub-Saharan AfricaBill & Melinda Gates Foundation · 2019–2027
- MPIUCF 234486-01Outcomes of Metastatic Urothelial Cancer Patients Selected for Surgery after ImmunotherapyAmerican Urological Association · 2024–2027
- PISAU 231848-01Improving Urology Standardized Letter of Recommendation and Development of an Electronic VersionSociety of Academic Urologists · 2023–2026
- PIUCF 228060-01Investigating the role of leptin in clear cell renal cell carcinoma and the obesity paradoxUrology Care Foundation · 2023–2026
Completed grants (2)
- PIOPP1158451Evaluation of the ShangRing vs. Mogen Clamp for Early Infant Male Circumcision in Sub-Saharan AfricaBill & Melinda Gates Foundation · 2016–2023
- KPU01AI075115-05EWOAcceptability and Safety of Shang Ring CircumcisionNational Institute of Allergy and Infectious Diseases · 2010–2012 · via The Johns Hopkins University
Clinical research
Active
1 study- PIThe MSKCC Bladder Oncogenome Living Biobank Project: Prospective Creation of Patient Derived Xenograft Models and OrganoidsMemorial Sloan Kettering Cancer Center · OPEN TO ACCRUAL (as of 2025)
Completed & closed trials (1)
- PINCT04131907A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of the Optilume™ BPH Catheter System in Men With Symptomatic BPHNA · Urotronic, Inc. · IRB STUDY CLOSURE (as of 2025)Benign Prostatic Hyperplasia
News mentions
- ShangRing Circumcision Device Could Boost HIV Prevention EffortsSeptember 13, 2022
An easy-to-use device for infant circumcision has proved to be safe in an international randomized controlled clinical trial led by Weill Cornell Medicine physician-scientists. The results suggest that the device could boost efforts to increase circumcision rates and prevent HIV in low-resource settings where early infant circumcision is not widespread.
External relationships
Ownership
Johnson & Johnson · Merck & Co., Inc. · Pfizer, Inc.
Speaker/Lecturer
American Urological Association